📊 JSPRW Key Takeaways
Is JSPRW a Good Investment? Thesis Analysis
Jasper Therapeutics is a pre-revenue biotech company with -$246K revenue, -$83.9M operating losses, and a -$77.2M operating cash burn rate, providing only ~4.5 months of cash runway at current burn rates. The weak equity position ($4.2M vs $31.6M liabilities) and deteriorating financial trajectory indicate unsustainable fundamentals with significant default risk.
Why Buy JSPRW? Key Strengths
- Strong liquidity position with 2.62x current ratio and quick ratio
- Substantial cash reserve of $28.7M providing near-term runway
- No long-term debt burden (0.00x debt/equity ratio)
JSPRW Investment Risks to Consider
- Negative and declining revenue (-113.9% YoY) indicating failed commercial traction
- Massive operating losses (-$83.9M) with unsustainable cash burn of -$77.2M per period
- Critically weak stockholders' equity ($4.2M) relative to liabilities ($31.6M) creates insolvency risk
- Minimal insider activity (1 Form 4 filing in 90 days) suggests low confidence from company leadership
- Limited cash runway of approximately 4.5 months based on current burn rate
Key Metrics to Watch
- Monthly operating cash burn rate and timeline to profitability or additional financing
- Revenue inflection point and path to positive revenue growth
- Stockholders' equity trend and solvency metrics
- Capital raise announcements or debt issuance to extend runway
JSPRW Financial Metrics
💡 AI Analyst Insight
The 31,366.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.62x current ratio provides a solid financial cushion.
JSPRW Profitability Ratios
JSPRW vs Healthcare Sector
How Jasper Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is JSPRW Overvalued or Undervalued?
Based on fundamental analysis, Jasper Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
JSPRW Balance Sheet & Liquidity
JSPRW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Jasper Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.89 indicates the company is currently unprofitable.
JSPRW Growth Metrics (YoY)
JSPRW Capital Allocation
JSPRW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Jasper Therapeutics, Inc. (CIK: 0001788028)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JSPRW
What is the AI rating for JSPRW?
Jasper Therapeutics, Inc. (JSPRW) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are JSPRW's key strengths?
Claude: Strong liquidity position with 2.62x current ratio and quick ratio. Substantial cash reserve of $28.7M providing near-term runway.
What are the risks of investing in JSPRW?
Claude: Negative and declining revenue (-113.9% YoY) indicating failed commercial traction. Massive operating losses (-$83.9M) with unsustainable cash burn of -$77.2M per period.
What is JSPRW's revenue and growth?
Jasper Therapeutics, Inc. reported revenue of $-246.0K.
Does JSPRW pay dividends?
Jasper Therapeutics, Inc. does not currently pay dividends.
Where can I find JSPRW SEC filings?
Official SEC filings for Jasper Therapeutics, Inc. (CIK: 0001788028) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JSPRW's EPS?
Jasper Therapeutics, Inc. has a diluted EPS of $-3.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JSPRW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Jasper Therapeutics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JSPRW stock overvalued or undervalued?
Valuation metrics for JSPRW: ROE of -1,826.1% (sector avg: 15%), net margin of 30,813.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JSPRW stock in 2026?
Our dual AI analysis gives Jasper Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is JSPRW's free cash flow?
Jasper Therapeutics, Inc.'s operating cash flow is $-77.2M, with capital expenditures of N/A. FCF margin is 31,366.3%.
How does JSPRW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 30,813.4% (avg: 12%), ROE -1,826.1% (avg: 15%), current ratio 2.62 (avg: 2).